Publications by authors named "Steve A Lubitz"
Article Synopsis
- A study was conducted to develop a polygenic risk score (PRS) specifically for aortic stenosis and compare its effectiveness against traditional clinical risk factors.
- This research involved analyzing data from large cohorts, including over 135,000 participants from the Million Veteran Program and various clinical trials between 2011 and 2020.
- The findings indicated that the new aortic stenosis PRS, which utilized millions of genetic variants, may provide significant risk estimation for the condition compared to established clinical methods.
Importance: The clinical utility of polygenic risk scores (PRS) for coronary artery disease (CAD) has not yet been established.
Objective: To investigate the ability of a CAD PRS to potentially guide statin initiation in primary prevention after accounting for age and clinical risk.
Design, Setting, And Participants: This was a longitudinal cohort study with enrollment starting on January 1, 2006, and ending on December 31, 2010, with data updated to mid-2021, using data from the UK Biobank, a long-term population study of UK citizens.
We conducted a multi-site investigation of genetic determinants of warfarin dose variability in Latinos from the U.S. and Brazil.
View Article and Find Full Text PDFBackground Only 50% of eligible atrial fibrillation ( AF ) patients receive anticoagulation ( AC ). Feasibility and effectiveness of electronic medical record (EMR)-based interventions to profile and raise provider AC percentage is poorly understood. The SUPPORT-AF (Supporting Use of AC Through Provider Profiling of Oral AC Therapy for AF) study aims to improve rates of adherence to AC guidelines by developing and delivering supportive tools based on the EMR to providers treating patients with AF.
View Article and Find Full Text PDFBackground: The epidemiology of atrial fibrillation (AF) without comorbidities, known as 'lone AF', is uncertain. Although it has been considered a benign condition, we hypothesized that it confers a worse prognosis compared with a matched sample without AF.
Methods: We described the proportion of AF without comorbidities (clinical, subclinical cardiovascular disease and triggers) among the entire AF sample in Framingham Heart Study (FHS).